Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cencora, Inc. Common Stock (NY:COR)

317.93 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cencora, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Cencora Announces Leadership Succession Plan
From Cencora
Via Business Wire
Here's How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
 
Via Benzinga
Critical Insights From Cencora Analyst Ratings: What You Need To Know
 
Via Benzinga
US Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation
FTC probes chemotherapy shortages, scrutinizing drug distributors and hospital groups. Root causes of drug shortages under scrutiny. Industry defends practices. 
Via Benzinga
Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today
 
Via Benzinga
Wednesday Is Your Last Chance To Buy Cencora Before The Dividend Payout
 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $12,000 Today
 
Via Benzinga
Peering Into Cencora's Recent Short Interest
 
Via Benzinga
How Is The Market Feeling About Cencora?
 
Via Benzinga
Why Walgreens Boots Alliance Stock Slumped 13.6% in January
The pharmacy giant ended an era. 
Via The Motley Fool
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
From Cencora
Via Business Wire
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
From Walgreens Boots Alliance
Via Business Wire
Cencora Closes $500 Million Senior Notes Offering
From Cencora
Via Business Wire
Here's How Much You Would Have Made Owning Cencora Stock In The Last 20 Years
 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Cencora Stock In The Last 15 Years
 
Via Benzinga
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
From Cencora
Via Business Wire
Drug Wholesale Firm Cencora Starts 2024 With Strong Growth, Lifts Annual Forecast On Commercial COVID-19 Vaccine Distribution
Cencora reports Q1 2024 results with adjusted EPS at $3.28 and revenue of $72.3 billion. Explore the company's fiscal year 2024 guidance and growth projections. 
Via Benzinga
Cencora Reports Fiscal 2024 First Quarter Results
From Cencora
Via Business Wire
Chart Of The Day: Cencora - Name Changed To Protect The Innocent?
Cencora, Inc. sources and distributes pharmaceutical products. 
Via Talk Markets
(COR) - Analyzing Cencora's Short Interest
 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,300 Today
 
Via Benzinga
How Is The Market Feeling About Cencora?
 
Via Benzinga
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
Cramer shared his insights during his attendance at JPMorgan's healthcare conference, 
Via Benzinga
Topics Artificial Intelligence
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
From Cencora
Via Business Wire
This 1 Surprising New Tailwind Is Lifting These 2 Evergreen Stocks
New growth drivers are helping to propel these reliable and steady businesses. 
Via The Motley Fool
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. 
Via Benzinga
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
3 Biotech Stocks You’ll Regret Not Buying Soon: November 2023
The global biotechnology market could nearly triple by 2030. Investors should consider buying these biotech stocks before they explode. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.